New drug combo offers hope for Hard-to-Treat leukemia patients
NCT ID NCT04746235
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in adults whose cancer has returned or not responded to prior treatment, as well as in older adults newly diagnosed who cannot tolerate strong chemotherapy. About 85 participants will receive the drug combination to see how many achieve remission and to monitor side effects. The goal is to improve disease control without the need for intensive chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.